As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $139.93M | $89.08M | $49.01M | $22.59M | $14.68M | $2.24M |
| Cost of Revenue | $40.98M | $35.31M | $27.68M | $18.08M | $12.97M | $4.06M |
| Gross Profit | $98.94M | $53.77M | $21.33M | $4.52M | $1.71M | $-1.82M |
| Gross Margin | 70.71% | 60.36% | 43.52% | 19.99% | 11.62% | -81.17% |
| Operating Expenses | $135.80M | $103.85M | $84.65M | $57.30M | $37.11M | $44.25M |
| Operating Income | $-36.86M | $-50.09M | $-63.32M | $-52.79M | $-35.41M | $-46.07M |
| Operating Margin | -26.34% | -56.23% | -129.21% | -233.64% | -241.21% | -2055.78% |
| Net Income | $-27.45M | $-48.61M | $-66.76M | $-48.69M | $27.57M | $126.22M |
| Net Margin | -19.62% | -54.57% | -136.22% | -215.50% | 187.87% | 5632.31% |
| EPS (Basic) | $-0.71 | $-1.41 | $-2.41 | $-1.78 | $0.18 | $0.95 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |